This site is intended for healthcare professionals only

Clinical trials

Filter:

Diabetes Distilled: The STEP trial programme – semaglutide and weight reduction
Multiple Interventions for Diabetic Foot Ulcer Treatment (MIDFUT) trial: benefits of involvement for patients and clinicians
GLP-1 receptor agonists significantly improve CV outcomes
GLP-1 receptor agonists have a wide range of benefits
Canagliflozin effective in primary and secondary prevention of CV outcomes
Renoprotection for patients with diabetes and kidney disease
Canagliflozin is cardioprotective in diabetic kidney disease
Semaglutide reduces cardiovascular risk in type 2 diabetes
Lowering LDL-cholesterol reduces CV event risk in diabetic dyslipidaemia
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.